TNF and systemic lupus erythematosus: Adalimumab, was the most frequently used tumor necrosis factor alpha (TNF-α) inhibitor amongst psoriasis patients with Crohn’s disease (34.7%), uveitis (22.3%), systemic lupus erythematosus (14.4%), autoimmune thyroiditis (11.7%), and lichen sclerosus (10%).